Both siRNA and miRNA can serve as powerful genesilencing reagents but their specific delivery to cancer cells in vivo without collateral damage to healthy cells remains challenging. We report here the application of RNA nanotechnology for specific and efficient delivery of anti-miRNA seed-targeting sequence to block the growth of prostate cancer in mouse models. Utilizing the thermodynamically ultra-stable three-way junction of the pRNA of phi29 DNA packaging motor, RNA nanoparticles were constructed by bottom-up self-assembly containing the anti-prostate-specific membrane antigen (PSMA) RNA aptamer as a targeting ligand and anti-miR17 or antimiR21 as therapeutic modules. The 16 nm RNase-resistant and thermodynamically stable RNA nanoparticles remained intact after systemic injection in mice and strongly bound to tumors with little or no accumulation in healthy organs 8 hours postinjection, and subsequently repressed tumor growth at low doses with high efficiency.
INTRODUCTION
Functionality of living organisms is made up by a wide variety of molecules consisting of DNA, RNA, and proteins. In the past, DNA has been used for its simplistic and defined structure in biomaterials, [1] [2] [3] [4] while proteins have extensively been utilized for their diverse structure and functionalities. 5 RNA brings together the characteristics of the simplicity of DNA and the wide variety of folding structures and functions of proteins, making it an attractive candidate for use in nanobiotechnology. 6, 7 Utilizing RNA in therapies provides several advantages over other technologies, including: known stoichiometry and defined folding of nanoparticles, thereby decreasing the possibility of side effects and toxicity. [8] [9] [10] [11] Multiple RNA moieties such as receptor-binding aptamer, 12, 13 siRNA, [14] [15] [16] ribozyme, [17] [18] [19] miRNA, [20] [21] [22] and riboswitch 23, 24 can be incorporated through the use of bottom up self-assembly. 8, 14 RNA nanoparticles normally are in the 10-50 nm size range, which is the optimal to pass through cell membranes through cell surface receptor mediated endocytosis while still being retained by the body but with little accumulation in organs. [25] [26] [27] Finally, RNA nanoparticles can prevent antibody detection by being protein free, but maintain their selectivity using receptor-binding aptamers. [28] [29] [30] The previous problem of instability of RNA nanoparticles once hindered the field of RNA nanotechnology 31 ; but 2'-Fluoro (2'-F) or -OMethyl modifications to uracil and cytosine backbones not only improves the thermodynamic stability but makes the resulting RNA resistant to RNase degradation. 32, 33 With these benefits, a stable RNA nanoparticle would prove to be a beneficial therapeutic delivery vehicle that could be used in the specific targeting and treatment of cancers and viral diseases.
Affecting one in every six men and being the second deadliest cancer in men (behind lung cancer), prostate cancer is a severe disease that affects a wide population. There are roughly 250,000 new cases of prostate cancer diagnosed each year with 30,000 deaths (American Cancer Society statistics). LNCaP cells are a class of prostate cancer cells known for being hormone dependent and androgen sensitive for growth. [34] [35] [36] Extensive work on prostate cancer therapies has previously been done using LNCaP cells as they are normally considered a less aggressive cancer. [37] [38] [39] [40] It is beneficial to use the early stage cancer cells as a target for therapies, as the tumor has not had time to develop into an aggressive state, is still hormonal dependent, and overall easier to manage than an hormone independent tumor. This allows for a contained treatment and a higher chance of successful removal of the disease. Furthermore, it has been shown that LNCaP tumor cells over express prostate-specific membrane antigen (PSMA), 36, [41] [42] [43] making it an even more attractive target as it can be easily identified from healthy prostate cells allowing for a specific targeting and delivery of therapeutics while having low toxicity effects on normally functioning prostate cells.
Within cancers, it has been found that many microRNA (miRNA) are either downregulated or overexpressed. [44] [45] [46] The differences in expression from healthy tissues have shown adverse downstream effects on many protein expressions, most notably leading to downregulation of tumor suppressors and increased antiapoptotic genes. LNCaP-FGC prostate cancer cells are known to have miR17 and miR21 play important roles, 47, 48 two common oncomirs that are commonly seen as important players in cancers. These two microRNAs lead to the downregulation of tumor suppressors such as PTEN and PDCD4 and upregulation of antiapoptotic genes. [48] [49] [50] [51] [52] [53] The regulation of these important oncogenes could correct the hindered tumor suppression and sensitize the cells to apoptosis. Recently anti-miRNA LNA sequences have been developed for miR17 and miR21, resulting in the silencing of their respective miRNAs. 54 Previously, a thermodynamically and chemically stable RNA three-way junction (3WJ) was discovered within the packaging RNA (pRNA) of the phi29 bacteriophage DNA packaging motor. 10 pRNA forms into a hexameric ring on the packaging connector and consists of two domains, the helical domain and central domain containing two interlocking loops. [55] [56] [57] [58] The two domains are connected together through a 3WJ that has been shown to form from three short RNA oligo strands in the absence of metal ions. 10 The junction also has the ability to harbor RNA moieties off each branch while still retaining the central folding structure of the 3WJ as well as the functionality of the RNA extensions. 10 This ultra-stable platform has proven to be a viable scaffold to carry RNA functionalities for the use in therapeutics in cancers and viral diseases. 10, [59] [60] [61] Using the pRNA-3WJ, we propose to create a RNA molecule with specific targeting ability to prostate cancer cells to carry miRNA LNAs. 54 Here, we report the use of the pRNA-3WJ for the construction of RNA nanoparticles for the specific targeting of prostate cancer tumor cells. LNCaP-FGC cells were used as in vitro cell model and the overexpression of the PSMA in LNCaP-FGC cells was used as a specific target. Targeting was achieved through the use of the PSMA A9g RNA aptamer that has been previously developed, 62, 63 and conjugated onto the pRNA-3WJ through bottom-up construction. Furthermore, we have conjugated anti-miRNA LNAs as well as fluorescent tags onto the remaining two branches of the three way junction for monitoring the binding and entry into the tumor cells. Nanoparticles were successfully constructed with defined stoichiometry and size that maintained the folding structures of both the pRNA-3WJ and A9g PSMA aptamer, keeping the functionality of the aptamer. The molecules further showed specific targeting to LNCaP-FGC cells in vitro through flow cytometry, cell confocal microscopy, and dual luciferase assays. Dual luciferase assays and qRT-PCR (quantitative Real Time Polymerase Chain Reaction) reported specific knockdown of miR21 and miR17 in LNCaP cells. Through these studies, we have proven that the combination of the A9g PSMA aptamer with anti-miRNA LNAs through the pRNA-3WJ into therapeutic nanoparticles, selective targeting to prostate cancer, specifically LNCaP-FGC cells, can be accomplished, providing a vehicle for therapeutical elements like siRNAs, miRNAs, or chemotherapies for tumor treatments.
RESULTS

Construction of pRNA-3WJ nanoparticles harboring PSMA binding aptamer
The truncated PSMA A9g aptamer was placed onto the pRNA-3WJ, creating a branched RNA motif to specifically target prostate cancer cells. RNA 3WJs were created with the PSMA aptamer attached to the 3WJ a /3WJ c branch in three different orientations (Figures 1 and 3 ) in order to test if there is any variation in the aptamer folding once placed on the pRNA-3WJ. Each of the three variants of the A9g-3WJ displayed proper folding and sizing on polyacrylamide gels ran in native conditions. Next, the prostate targeting 3WJs were tested for nuclease and thermodynamic stability. First each of the 2'-F modified A9g-3WJs were incubated with 10% fetal bovine serum over 24 hours (Figure 2a) . Samples were then run on polyacrylamide gels, where the band corresponding to the assembled RNA nanoparticles remained stable throughout all time points. This data shows that the RNA nanoparticles will remain stable during in vivo applications as RNases are not able to recognize and degrade the fluoro-modified nucleic acids. Furthermore, the thermodynamic stability of the PSMA targeting 3WJ was assayed using temperature-gradient gel electrophoresis. Temperature gradient was applied perpendicular to the electrical current in order to find the melting temperature of the 3WJ harboring the aptamer (Figure 2b) . Previously, the melting temperature (T M ) of 2'-F-modified pRNA-3WJ core was found to be 69.8 °C. 64 From the temperature-gradient gel electrophoresis melting curve, the melting temperature of the A9g-3WJ was found to be 61.2 °C. Although the T M of the aptamer-3WJ complex is less than the 3WJ itself, the still rather high melting temperature of the nanoparticle indicates the PSMA A9 aptamer does not significantly hinder the stability of the pRNA-3WJ core, and in fact the 3WJ actually provides added stability to the PSMA aptamer.
After establishing that A9g-3WJ displayed the high stability previously seen in the pRNA-3WJ, the targeting 3WJ was expanded to harbor anti-miRNA LNAs for testing the delivery of therapeutics to LNCaP-FGC cells (Figure 1c) . The extension of the unoccupied branch of the 3WJ posed no problem in folding of the RNA strands, as all completed nanoparticles were assayed on polyacrylamide gels ran in native conditions (Figure 1d) . Assembly gels showed high yield of the folded RNA nanoparticle, with any side product bands being contributed to mismatch in RNA concentrations during assembly. Within the assembly gel, two bands were seen from the A9g-3WJ strand and the A9g-3WJ-anti-miRNA samples; this was attributed to formation of a self-dimer of the A9g aptamer. Furthermore, assembled nanoparticles, A9g-3WJ and A9g-3WJ-anti-miR21 LNA, were tested for zeta potential and hydrodynamic size (Figure 2c) . Here, it was found that the size of the nanoparticles were 3.77 ± 0.59 and 4.27 ± 0.32 nm, with a zeta potential of −18.0 ± 1.45 and −22.87 ± 2.40 mV, respectively. These values are in line with predictions and previously published results of other RNA nanoparticles.
65-67
Targeting of pRNA-3WJ nanoparticles to LNCaP-FGC cells In order to test the targeting of the pRNA-3WJ, either a fluorescent Alexa 647 or whole chain labeling with Cy5 fluorophore was placed on the 3WJ b strand to allow for tracking of the RNA nanoparticles created and described above. The A9g-3WJ nanoparticles were incubated with LNCaP-FGC cells, as well as PC-3 cells (PSMA−) as a negative control. Following the RNA incubation and washing steps cells were analyzed by flow cytometry to confirm the binding of each of the three A9g-3WJs. FACS data from each of the designs showed strong binding (>75%) to LNCaP-FGC cells while the aptamernegative pRNA-3WJ displayed only 6.59% binding (Figure 3) . However, with this high binding, it was found that the two designs with hinging aptamers produced an increased and undesired nonspecific binding to PC-3 cells. Therefore connecting the A9g PSMA aptamer to the pRNA-3WJ directly to the two helical regions of the 3WJ a /3WJ c branch provided the highest binding to LNCaP-FGC (91.22%), while having low non-specific binding to PSMA-PC-3 cell line (11.60%) ( Table 1) . Flow cytometry data displayed that the addition of the pRNA-3WJ to the end of the PSMA A9g aptamer did not interrupt cell binding, and provided a branched scaffold for the addition of therapeutic elements such as siRNAs, miRNAs, and anti-miRNAs. Next, endocytosis entry of the RNA nanoparticles harboring the PSMA A9g aptamer into LNCaP-FGC cells was examined. In order for proper delivery of therapeutics and RNA nanoparticles to act as anticancer agents, entry into the cells are required for proper release of therapeutic agents. Alexa 647 -labeled A9g-3WJ nanoparticles were incubated with LNCaP-FGC and PC-3 cells, cells were then fixed and the nuclei and cytoplasm were stained. Confocal microscopy images shows proper binding of the A9g aptamer to LNCaP cells with very little signal seen on PC-3 cells. Furthermore, confocal imaging along with Z-axis stacking imaging (Figure 4 ) confirmed Alexa 647 signal within LNCaP-FGC cells on A9g-positive nanoparticles. Additionally, little Alexa 647 signal was seen around cells samples without the PSMA aptamer and the signal was only seen accumulating around the LNCaP cells and not within. Additionally, cell binding assays were completed using VCaP (PSMA+) and Jurkat (PSMA−) cell lines to further test the specificity of the A9g-3WJ nanoparticles (data not shown).
Delivery of anti-miRNA LNA to LNCaP-FGC cells
Anti-miRNA LNA targeting miR21 and miR17 were placed onto the PSMA A9g-3WJ by a DNA linker strand for delivery into LNCaP-FGC cells. 65 Incubation studies of the RNA nanoparticles harboring the PSMA RNA aptamer with the miR17 and miR21 were then tested for the delivery using Promega's psi-check2 dual luciferase plasmid. The transfected plasmid contained sequences for Firefly and Renilla luciferase plasmids with each plasmid containing the microRNA targeting sequences at the 3'-UTR region of Renilla luciferase, respectively. Therefore in the native cells, the Renilla expression is knocked-out, as the miRNA binds to plasmid, preventing the translation of Renilla luciferase proteins, but Firefly expression remains unaffected. As anti-miRNA LNA sequences are delivered to the cells, miR17 and miR21 are knocked-down, thus resulting in an increased expression of Renilla in the dual luciferase assay. By incubating RNA nanoparticles with LNCaP and PC-3 cells, miR17 and miR21 knock-down was assayed by the described dual luciferase assay. Data in LNCaP-FGC cells shows significant increase in Renilla expression in the A9g-3WJ-anti-miRNA LNA and anti-miRNA LNA transfected samples; however, little effect seen from PSMA aptamer negative samples for both miR17 and miR21 (Figure 5b) . This shows the anti-miRNA sequences are being properly delivered to LNCaP-FGC cells by the PSMA A9g aptamer and processed by RISC. Additionally, studies completed in PC-3 cells showed significantly less increase in Renilla expression from the A9g-3WJ-anti-miRNA LNA samples, indicating RNA nanoparticles were selectively targeting LNCaP cells through PSMA binding, indicating a low toxicity to PSMA-cell lines. Furthermore, due to the fact that the aptamer sequence is on a different strand from the anti-miRNA sequences, these studies indicate that the RNA nanoparticles are remaining stable and intact through the pRNA-3WJ core throughout the studies.
To further confirm the delivery of anti-miRNA LNA sequences into LNCaP-FGC cells and the ability for the LNAs to effect downstream gene expressions, quantitative real-time PCR was completed, examining the expression of PTEN and PDCD4, known downstream genes of both miR17 and miR21. 18S was used as an internal control during these experiments to standardize the expressions of PTEN and PDCD4 mRNA. q-rtPCR results show significant increase of PTEN at only a 10 nmol/l concentration of RNA nanoparticles in the A9g-3WJ-anti-miR21 samples over the negative controls (Figure 5c ). Additionally, it was seen that the RNA nanoparticles were able to slightly increase the PDCD4 expression over negative controls and the cell only samples. These data further prove the delivery of anti-miRNA LNAs to LNCaP-FGC cells through the A9g-3WJ complex. Furthermore, the increase of tumor suppressor genes not only shows a true knockdown of the miRNAs, but displays the RNA nanoparticles' ability to correct errors in gene expressions caused by the prostate cancer.
From the confirmed upregulation of tumor suppressor genes by delivery of miRNA LNAs by the 3WJ, testing of apoptotic effects were completed through assaying Caspase III signaling on LNCaP-FGC and PC-3 cells after incubation with A9g-3WJ-anti-miRNAs along with negative nanoparticle controls described before (Figure 6) . The PC-3 cells and negative RNA nanoparticles with LNCaP cells were used to show the RNA nanoparticles were not toxic to the cells and apoptosis only occurred through specific delivery of the anti-miRNA LNAs. A spike in Caspase III signaling was seen in LNCaP cells treated with A9g-3WJ-anti-miR17 and transfected by RNAi Max anti-miRNA LNAs (Figure 6 ). This indicates that the silencing of miRNA was able to successfully lead to the death of LNCaP cells. Here, apoptosis caused by the decreased expression of miR17 shows the important role of the miRNA in LNCaP cells and the ability to control the cell growth and death through its expressions.
In vivo delivery of anti-miRNA LNA to LNCaP Subcutaneous xenograft tumors were developed in male nude mice with LNCaP C4-2 cells. Once tumors were fully developed (2 weeks) with cardio vasculature, 100 μl of 20 μmol/l solution of pRNA-3WJ nanoparticle harboring the PSMA A9g aptamer along with an Alexa 647 fluorescent tag were administered to the mice through tail-vein injection. For all in vivo studies, nanoparticles were injected and delivered as bare oligos without the aid of any additives. Through a series of time points, mice were whole body imaged to examine the biodistribution of nanoparticles, along with the accumulation in tumors as well as healthy organs. Initially Alexa 647 was detected throughout the whole body of the mice indicating nanoparticles successfully circulated through the mice. Through early time points, Alexa 647 concentrated in the tumor, liver, and bladder of the mice; indicating the excess nanoparticles were excreted through the urine. After 8 hours, fluorescence signal was undetectable in all healthy organs, while remaining strong in the xenograft tumor (Figure 7a) . Additionally, tumors were sectioned and imaged for fluorescent imaging (Figure 7c) . Confocal imaging shows specific targeting and accumulation of the A9g-3WJ nanoparticles to the LNCaP xenograft tumor. This indicates nanoparticles have no lasting Furthermore, the therapeutic effects of the A9g-3WJ-anti-miRNA nanoparticles were tested in vivo on LNCaP C4-2 subcutaneous xenografts. After tumors were developed to a volume of ~200 mm 3 , nanoparticles harboring the anti-miR17 and -miR21 LNAs were administered to the mice through a series of five tail-vein injections. Tumor volume and total weight of the mice were monitored throughout this experiment. From the tumor volume data (Figure 7b) , it can clearly be seen that the A9-3WJ-antimiRNA samples led to a stunted tumor growth and proliferation compared to negative controls, thus indicating the anti-miRNA oligos had a profound effect on the tumor environment and cell growth. Even after postadministration of the nanoparticles, a lack of growth in the tumors was seen for several days compared to nontreated tumors. Furthermore, there was no significant change in the mice weights over the observed RNA nanoparticle delivery indicating no toxicity in the mice and the tumor reduction was as a result of specific delivery to the tumors.
At the conclusion of in vivo delivery of the pRNA-3WJ nanoparticles, mice were sacrificed and tumors were harvested. PTEN and PDCD4 expressions were measured in the tumors, using β-Actin as an internal control. Western blots (Figure 7d) show an increase in PTEN and PDCD4 in the pRNA-3WJ nanoparticles harboring the anti-miRNA LNAs. These results display the same ability of the pRNA-3WJ nanoparticles as seen in vitro with the LNCaP cells, as the anti-miRNA sequences led to the increase of expression tumor suppressor genes as a result of decreased miR21 and miR17 expressions. On average an increase was seen in the A9g-3WJ sample over the control but less than A9g-3WJ-anti-miRNA groups. This may have been due to the repeated dosage of the RNA to the tumor cell in the animal trials, the larger volume of the nanoparticle may have had an effect on the gene expression within the tumor; however, the change in gene expression was not enough to create a change in tumor growth as shown in Figure 7b .
DISCUSSION
An RNA aptamer using 2′-Fluoro-modified nucleotides was generated through SELEX for specific targeting of PSMA by Lupold et al. 62 Furthermore, Rockey et al. 63 rationally truncated the A9 PSMA aptamer to shorten the overall length while keeping the high specificity to PSMA. It is well known that prostate-specific membrane antigen is overexpressed in LNCaP-FGC prostate cancer cells. 35, 36, [68] [69] [70] [71] 35, 36, [64] [65] [66] [67] PSMA is an important target since it is overexpressed in primary prostate tumors as well as metastases in the lymph nodes. 72, 68 Furthermore, PSMA has been shown to be upregulated in tumors after patients have been treated with common androgen-deprivation therapies. 70, 73, 66, 69 The truncated PSMA A9g aptamer was placed onto the pRNA-3WJ, creating a branched RNA motif to specifically target prostate cancer cells.
Resulting nanoparticles display that PSMA A9g aptamer is not only specifically binding to PSMA + cells, but entering through receptor mediated endocytosis as expected. Here, very similar binding profiles between flow cytometry and confocal microscopy were seen with LNCaP cells further confirming the targeting of the A9g aptamer. With positive detection of nanoparticles in the LNCaP-FGC cells, it is possible to deliver therapeutics in hopes of leading to apoptosis of LNCaP cells through RNA interference (RNAi).
Upon confirmation of PSMA targeting nanoparticles entering into LNCaP-FGC cells, experiments were expanded to test the delivery of therapeutic components. LNCaP-FGC cells are known to overexpress miR17 and express miR21, two common oncomirs that are seen in cancers. 47, 48 These two microRNAs lead to the downregulation of tumor suppressors such as PTEN and PDCD4 and upregulation of antiapoptotic genes. [48] [49] [50] [51] [52] [53] Additionally, miR-21 has been shown to promote hormone independency prostate cancers 74 and enhances the invasiveness of LNCaP cells 75 ; while miR17 has been proven to promote tumor growth and invasiveness in prostate cancer cells. 76 Therefore, silencing miR17 and miR21 could lead to the sensitization of the LNCaP-FGC cells leading to apoptosis. Anti-miRNA sequences have been developed to target, and bind miR17 and miR21, thus blocking their genesilencing roles. 54 The prostate cancer targeting RNA nanoparticles delivering the anti-miRNA LNAs shows the vast possibility of RNA nanoparticles. Here, we show constructed nanoparticles using the pRNA-3WJ were stable in fetal bovine serum, being resistant to RNases and stable at temperatures well above the 37 °C needed for in vivo applications. Furthermore, the 3WJ harboring the PSMA aptamer and anti-miRNA LNAs and positive functionality of each shows the versatility of the pRNA-3WJ to harbor RNA moieties while keeping the original functionality of each of the RNA groups, i.e., the targeting and binding of the PSMA aptamer and the silencing ability of the anti-miRNA LNAs. The LNCaP prostate cancer-specific nanoparticles produces excellent binding profiles, displaying binding at over 90% at 100 nmol/l RNA concentrations and later proved to provide specific delivery of anti-miRNA sequences for the knockdown of miR17 and miR21. Significant knockdown of miR17 and miR21 and upregulation of PTEN indicated the positive and specific delivery by the pRNA-3WJ RNA nanoparticles in in vitro and in vivo. We have demonstrated not only the ability of the RNA nanoparticles to accumulate and target the tumor specifically with high affinity, but deliver antioncogenic RNA sequences to regulate tumor growth and development of tumors.
Through these studies, RNA nanoparticles have been developed that have the capability to target tumors primary and metastatic tumors as well tumors after hormone deprivation treatments. Furthermore, anti-miRNA sequences have been shown to control tumor growth and proliferation, while having the possibility to prevent PSMA tumors from transitioning to hormonal independent states. Overall, stable RNA nanoparticles can be constructed for the specific targeting and treatment of cancers, and past hurdles that have held back the field of RNA nanotechnology are no longer a concern. 
CONCLUSIONS
RNA nanoparticles were constructed using the pRNA-3WJ core from the phi29 packaging motor for specific targeting and treatment of prostate cancer cells. RNA nanoparticles were proven to remain chemically and thermodynamically stable after the addition of functional groups off each branch. The LNCaP prostate cancer-specific nanoparticles produces excellent binding profiles, displaying binding at over 90% at 100 nmol/l RNA concentrations and later proved to provide specific delivery of antimiRNA sequences for the knockdown of miR17 and miR21, two common oncogenes. Significant knockdown of miR17 and miR21 and upregulation of PTEN indicated the positive and specific delivery by the pRNA-3WJ RNA nanoparticles in in vitro and in vivo.
MATERIALS AND METHODS
Design and construction of pRNA-3WJ nanoparticles harboring PSMA binding aptamer and anti-miRNA LNA. RNA nanoparticles were constructed using a bottom-up approach, as previously described. Briefly, DNA oligos primers (Integrated DNA Technologies, Coralville, Iowa) were used to create dsDNA templates through polymerase chain reaction (PCR) for each RNA strand. RNA strands were then transcribed by T7 polymerase in vitro. Additionally, 2'-fluoro (2'-F)-modified cytosine and uracil were used in transcriptions along with an Y639F-mutant T7 polymerase, giving nuclease stability to the RNA strands. The anti-micro RNA LNAs were synthesized by Exiqon (Woburn, MA). Transcribed RNA strands were purified on 8% polyacrylamide gels containing 8 mol/l Urea ran at 120 V for 1.5 hours on TBE running buffer (89 mmol/l Tris-borate, 2 mmol/l Ethylenediaminetetraacetic acid (EDTA)). RNA bands of interest were excised from the gel using UV shadow on thin layer chromatography plates and eluted from gel in elution buffer (0.5 M Ammonium Acetate, 0.1 mmol/l EDTA, 0.1% SDS) at 37 °C for a minimum of 3 hours and then precipitated by ethanol.
RNA nanoparticles were assembled by mixing strands at equal molar concentrations in TMS buffer (50 mmol/l Tris pH 8.0, 100 mmol/l NaCl, 10 mmol/l MgCl 2 ) and heated to 80 °C for 5 minutes and slowly cooled over 40 minutes to 4 °C. Assembled RNA nanoparticles were then purified on 8% polyacrylamide gels at 100 V for 2 hours on TBM running buffer (89 mmol/l Tris, 200 mmol/l borate acid, and 5 mmol/l MgCl 2 ) and at 4 °C. Samples were then excised and eluted as described above.
Temperature-gradient gel electrophoresis assay for studying thermodynamic stability of RNA nanoparticles. For temperature-gradient gel electrophoresis analysis, the experimental setup was adjusted to have a linear temperature gradient perpendicular to the electric field (BiometraHmbGh, Göttingen, Germany). The temperature gradient was set from 36.0 to 80.0 °C. RNA sample (500 nmol/l) was combined with 6× gel-loading buffer and run on 8% native polyacrylamide gel at 100 V for 1 hour. 10 mmol/l MgCl 2 was present in both gel and electrophoresis buffer. The nanoparticles contained a Cy5 fluorophore on the 3WJ b strand for monitoring melting and imaged by Typhoon FLA 7000 (GE Healthcare, Pittsburgh, PA). The pRNA-3WJ constructs within the total RNA was analyzed by ImageJ, and the melting curve of the construct was fitted using nonlinear Sigmoidal fitting. Melting temperatures (T M ) were calculated where 50% of total RNA concentration was at ssRNA and 50% was in complexed 3WJ form.
Serum stability assay for studying chemical stability of RNA nanoparticles. Four hundred nanograms of pRNA-3WJ nanoparticle were incubated in TMS buffer containing fetal bovine serum (final concentration is 10%). The total volume was 10 µl. Samples were taken at multiple time points, including 0, 0.25, 0.5, 1, 2, 6, 12, and 24 hours after incubation at 37 °C. 8% Native TBM PAGE gel electrophoresis was applied to visualize RNA. After running for 1.5 hours at 4 °C, the gel was stained by ethidium bromide. Images were taken by Typhoon FLA 7000 (GE Healthcare).
Dynamic light scattering and zeta potential measurement of RNA nanoparticles. Apparent hydrodynamic sizes and zeta potential of preassembled A9g-3WJ-anti-miR21 LNA and A9g-3WJ nanoparticles were measured by a Zetasizer nano-ZS (Malvern Instrument, Malvern, UK). All RNA samples were measured at 2 μmol/l in Diethylpyrocarbonate H 2 O and PBS buffer (137 mmol/l NaCl, 2.7 mmol/l KCl, 100 mmol/l Na 2 HPO 4 , 2 mmol/l KH 2 PO 4 , pH 7.4) at 25 °C.
Cell culture. Human prostate cancer cell lines LNCaP-FGC, LNCaP C4-2 and PC-3 (American Type Culture Collection, Manassas, MA) were grown and cultured in RPMI 1640 medium (Invitrogen, Grand Island, NY) containing both 10% fetal bovine serum and penicillin/streptomycin in a 37 °C incubator with a 5% CO 2 and a humidified atmosphere. Dual luciferase assay to analyze delivery of anti-miRNA by pRNA-3WJ nanoparticles. LNCaP-FGC and PC-3 cells were grown on 24-well plates in RPMI-1640 medium until reaching ~80-90% confluency. 100 and 50 nmol/l A9g-3WJ-anti miRNA LNA and the control RNAs including pRNA-3WJ/anti-miRNA-(17 or 21) LNA and A9g-3WJ were incubated with cells in opti-modified essential media (MEM) at 37 °C for 3 hours. As a positive control, anti-miRNA LNA transfected by RNAi MAX (following standard protocol by Invitrogen) into cells, while complete nanoparticles were merely incubated with cells. After incubation with the RNA, cells were washed once with blank RPMI-1640 medium and then transfected with psi-Check 2 plasmid (Promega, Madison, WI) which contains an oncogenic miRNA targeting sequences at the 3'-UTR region of Renilla Luciferase gene using Lipofectamine 2000 (Life Technologies, Carlsbad, CA). Dual-luciferase assay (Promega) was used to evaluate the anti-miRNA LNA effects 24 hours post-transfection upon manufacture's instruction. Briefly, cells were washed once with PBS and lysed with passive lysis buffer. The plates were shaken for 30 minutes at room temperature. 20 μl of the lysate were added to 50 μl of luciferase assay reagent (LAR II) in a luminometer tube and firefly luciferase activity was measured. Upon addition of 50 μl of Stop & Glo Reagent, control measurements of Renilla luciferase activity were then obtained. The Renilla luciferase activity obtained was then normalized with respect to the Firefly luciferase activity for determining the average ratio of Renilla to Firefly luciferase activity over several trials. Results were statistically analyzed by an analysis of variance two-way test in comparing Renilla expression to the cell only control and between PC-3 and LNCaP cell lines among each concentration.
Molecular Therapy
qRT-PCR assay. Two A9g-pRNA-anti-miRNA LNA constructs were assayed for the subsequent gene upregulation effects: one harboring antimiR21 LNA, and the other harboring anti-miR17 LNA.
LNCaP-FGC cells were incubated with 10 and 100 nmol/l of the individual A9g-3WJ-anti-miRNA LNA and control RNAs as described above. After 72-hour treatment, cells were collected and target gene upregulation effects were assessed by qRT-PCR. PC-3 cells were used as negative control cell line.
Cells were processed for total RNA using Trizol RNA extraction reagent following manufacture's instruction (Life Technologies). The first cDNA strand was synthesized on total RNA (1 μg) from cells with the various RNAs treatment using SuperScript III First-Strand Synthesis System (Invitrogen). Real-time PCR was performed using Taqman assay. All reactions were carried out in a final volume of 20 μl using Taqman Fast Universal PCR Master Mix and assayed in triplicate. Primers/probe set for human PTEN and 18S were purchased from Life Technologies. PCR was performed on
Step-One Plus real time PCR system (Applied Biosystem, Foster City, CA). The data were analyzed by the comparative C T Method (ΔΔC T Method). Mice were then administered PBS (blank control), pRNA-3WJ (negative control), and A9g-3WJ each with Alexa 647 labels as naked oligos at a dose of 2 μmol/l at 100 μl through the tail vein. Mice were imaged for whole body fluorescence at time points 0, 1, 2, 3, 4, and 8 hours with an In Vivo Imaging System (IVIS) imager (Caliper Life Sciences, Waltham, MA). Upon the completion of the study, mice were sacrificed, and tumors, hearts, kidneys, livers, and brains were collected and imaged by the whole body imager for Alexa 647 signal.
Furthermore, tumors were fixed in 4% paraformaldehyde with 10% sucrose in 1× PBS buffer at 4 °C overnight. Tumor samples were then placed in Tissue-Tek Optimum Cutting Temperature compound (Sakura Finetek USA, Torrance, CA) for frozen sectioning (10 μm thick). Sectioned tissue were then stained with DAPI (4′,6-diamidino-2-phenylindolem dihydrochloride) and mounted with ProLong Gold Anti-fade Reagent (Life Technologies) overnight. Slides were then fluorescently imaged by FluoView FV1000-Filter Confocal Microscope System (Olympus, Pittsburgh, PA).
In vivo tumor reduction by anti-miRNA LNA pRNA-3WJ nanoparticles.
LNCaP C4-2 cells were grown and subcutaneously injected into 4-weekold male nude mice. 2 × 10 6 cells were injected as a 50% cell, 50% Matrigel (Corning, Corning, NY) blend into the flank of the mice with a total of five mice hosting two tumors each. Xenograft tumors were monitored until they reached roughly 200 mm 3 in volume. Naked RNA nanoparticles harboring the PSMA A9g aptamer and anti-miRNA LNAs were injected through the tail vein of mice at a concentration of 20 μmol/l at 100 μl on days 7, 10, 13, 17, and 20 while monitoring tumor volume and total mouse weight up to day 29.
Western blot of miRNA downstream genes of xenograft tumors. Upon the completion of tumor reduction experiments, mice were sacrificed and tumors were harvested. LNCaP C4-2 tumors were homogenized in RIPA buffer containing Protease (ThermoFisher, Waltham, MA). Total protein concentration was measured by BCA protein assay (ThermoFisher) against protein standards. Hundred micrograms of total protein from the tumor were loaded onto TDX FastCast SDS PAGE gels (BioRad, Hercules, CA) and ran at 100 V for 2 hours. Gels were transferred onto membranes and stained with PTEN, PDCD4, and β-Actin antibodies (Cell Signaling, Danvers, MA) and imaged. β-Actin was used as an internal control and PTEN and PDCD4 are expressed as a ratio with β-Actin.
